Artificial Intelligence
4D Molecular Therapeutics Announces Collaboration on Leading Machine Learning Technology and Expertise from U.C. Berkeley to Expand Therapeutic Vector Evolution Platform
EMERYVILLE, Calif., May 04, 2021 (GLOBE NEWSWIRE) — 4D Molecular Therapeutics (Nasdaq: FDMT), a clinical-stage gene therapy company harnessing the power of directed evolution for targeted gene therapies, announced a new collaboration with investigators at the University of California, Berkeley focused on expanding the vector invention power of 4DMT’s Therapeutic Vector Evolution platform by applying machine learning technology to the AAV vector capsid datasets generated from 4DMT’s platform. This research will be conducted with Jennifer Listgarten, Ph.D., a global leader in machine learning and computational biology, and David Schaffer, Ph.D., a global leader in AAV directed evolution and gene therapy. Dr. Listgarten is a Professor in U.C. Berkeley’s Center for Computational Biology, the Berkeley Artificial Intelligence Research Lab and the Chan Zuckerberg Biohub. Prior to her current positions, she held leadership roles in machine learning within Microsoft Research for approximately 10 years. Dr. Schaffer is Professor of Chemical and Biomolecular Engineering, Molecular and Cell Biology and the Helen Wills Neuroscience Institute at U.C. Berkeley. He is also Co-founder, Director and Chief Scientific Advisor at 4DMT.
“This cross-functional collaboration with world leaders in machine learning and AAV gene therapy technologies gives us the potential to dramatically expand the depth and breadth of targeted and evolved vectors invented through our Therapeutic Vector Evolution platform, significantly expanding our leading vector patent and product portfolios. 4DMT’s industry-leading AAV capsid libraries encompass over one billion synthetic capsid sequences. To our knowledge, we have the largest capsid biodistribution datasets in the world as a result of the over 15 vector selection programs we have conducted in non-human primates,” said David Kirn, M.D., Co-founder and Chief Executive Officer of 4DMT. “This partnership with Drs. Listgarten and Schaffer empowers 4DMT to dramatically expand our bioinformatics capabilities, enabling us to identify even more promising vectors both within, and even beyond, our existing libraries. This partnership reaffirms our commitment to relentless innovation in order to bring cures to patients.”
Therapeutic Vector Evolution combines the power of directed evolution with approximately one billion synthetic capsid sequences to invent evolved vectors for use in targeted gene therapy products. Using its proprietary Therapeutic Vector Evolution platform, to date 4DMT has generated an industry-leading 40 distinct capsid libraries, conducted more than 15 vector selections in non-human primates, and has filed patent applications on over 300 novel AAV vectors. Three of these proprietary vectors were used in clinical and/or IND product candidates in ophthalmology (4D-150, 4D-125, 4D-110), cardiology (4D-310) and lung (4D-710). Through these 15 vector selections, 4DMT has generated numerous industry leading and expansive datasets relating to capsid biodistribution and delivery to targeted tissues through routine routes of administration, efficient transduction of target cells, and/or resistance to neutralizing antibodies. The application of machine learning to 4DMT’s Therapeutic Vector Evolution and its datasets represents an opportunity to leverage an enabling technology to invent new vectors for use in targeted gene therapy products.
About 4DMT
4DMT is a clinical-stage company harnessing the power of directed evolution for targeted gene therapies. 4DMT seeks to unlock the full potential of gene therapy using its platform, Therapeutic Vector Evolution, which combines the power of directed evolution with approximately one billion synthetic capsid sequences to invent evolved vectors for use in targeted gene therapy products. The company is initially focused in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The 4DMT targeted and evolved vectors are invented with the goal of being delivered through clinically routine, well-tolerated and minimally invasive routes of administration, transducing diseased cells in target tissues efficiently, having reduced immunogenicity and, where relevant, having resistance to pre-existing antibodies. 4DMT is currently conducting three clinical trials: 4D-125 is in a Phase 1/2 clinical trial for XLRP patients, 4D-110 is in a Phase 1 clinical trial for choroideremia patients and 4D-310 is in a Phase 1/2 clinical trial for Fabry disease patients.
4D Molecular Therapeutics™, 4DMT™, Therapeutic Vector Evolution™, and the 4DMT logo are trademarks of 4DMT.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, implied and express statements regarding plans and timelines for the clinical development of 4D-310, 4D-125, 4D-110, 4D-150 and 4D-710, including the therapeutic potential and clinical benefits thereof; 4DMT’s potential to dramatically expand the depth and breadth of the proprietary optimized vectors invented through its Therapeutic Vector Evolution platform and its ability to expand its vector patent portfolio; whether 4DMT’s machine learning collaboration with U.C. Berkeley will expand its bioinformatics capabilities and whether 4DMT will be able to identify additional promising synthetic capsid sequences within its existing libraries; whether 4DMT’s machine learning collaboration with U.C. Berkeley could drive additional value and result in the discovery of novel new capsids; and 4DMT’s strategy, business plans and focus. The words “may,” “might,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “expect,” “estimate,” “seek,” “predict,” “future,” “project,” “potential,” “continue,” “target” and similar words or expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management’s current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, risks associated with: the impact of COVID-19 on countries or regions in which 4DMT has operations or does business, as well as on the timing and anticipated results of its clinical trials, strategy and future operations; the delay of any current or planned clinical trials for the development of 4DMT’s drug candidates, the risk that the results of its clinical trials may not be predictive of future results in connection with future clinical trials; 4DMT’s ability to successfully demonstrate the safety and efficacy of its drug candidates; the timing and outcome of our planned interactions with regulatory authorities; and obtaining, maintaining and protecting our intellectual property. These and other risks and uncertainties are described in greater detail in the section entitled “Risk Factors” in 4DMT’s most recent Annual Report on Form 10-K that was filed on March 25, 2021, as well as any subsequent filings with the Securities and Exchange Commission. In addition, any forward-looking statements represent 4DMT’s’ views only as of today and should not be relied upon as representing its views as of any subsequent date. 4DMT explicitly disclaims any obligation to update any forward-looking statements. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements.
4D-310, 4D-125 and 4D-110 are 4DMT’s product candidates in clinical trials and have not yet been approved for marketing by the US FDA or any other regulatory authority. No representation is made as to the safety or effectiveness of 4D-310, 4D-125, or 4D-110 for the therapeutic use for which they are being studied.
Contacts:
Media:
Theresa Janke
[email protected]
Investors:
Mike Zanoni
Endurance Advisors
[email protected]
Artificial Intelligence
Add Value Machine, ADCB and Amazon Web Services (AWS) Successfully Conclude UAE’s First-Ever Generative AI Hackathon in the Banking Sector
ABU DHABI, UAE, June 17, 2024 /PRNewswire/ — Add Value Machine (AVM), a leading provider of secure generative AI platforms, and Abu Dhabi Commercial Bank (ADCB), one of the largest banks in the UAE, have successfully concluded the groundbreaking ADCB Generative AI Hackathon. The event, which took place in Abu Dhabi, marked the first time a UAE bank has conducted a hackathon focused on exploring the potential of generative AI in the banking sector.
“We are thrilled to have partnered with ADCB and AWS to host this groundbreaking hackathon,” said John Shaw, CEO of Add Value Machine. “Our secure generative AI platform has enabled ADCB to explore innovative solutions that can drive meaningful business impact across the bank. This event showcases the immense potential of generative AI in the banking sector, and we look forward to working with ADCB to bring the most impactful use cases into production.”
The hackathon brought together nearly 120 participants from ADCB, AVM and Amazon Web Services (AWS) collaborated to structure the event around key business outcomes, focusing on the most relevant ROI generative AI use cases in procurement, engineering, retail banking, and treasury.
Sean Langton, ADCB’s CIO, reflected on the event’s success, stating, “Generative AI is the perfect technology for a hackathon – it has unlimited opportunity to improve our business and customer experience but also presents emerging risks we need to be mindful of. Thanks to our partnerships with Added Value Machine and AWS, we’ve been able to build several AI ‘bots’ in a safe way in just a day. I can’t wait to see the first of these up and running in production in the coming days.”
All use cases developed during the hackathon were built on AVM’s observability, governance and compliance generative AI platform. AVM and AWS are now working closely with ADCB to accelerate the most impactful use cases into production, ensuring that the bank can quickly realize the benefits of generative AI technology.
Ravi Singh, President and CTO of Add Value Machine, expressed his enthusiasm for the collaboration, stating, “It’s inspiring to witness the passion and unity of purpose at ADCB. The combination of visionary leadership and technical expertise has resulted in a thoughtful, measured approach to generative AI adoption. We are proud to be part of this transformative journey.”
ADCB plans to conduct regular hackathons to foster a culture of innovation and explore new applications of generative AI technology across its business operations.
About Add Value Machine:AVM is a leading Generative AI security company that provides 360-degree observability, enabling enterprises to monitor all of the Generative AI usage no matter where it happens. The accelerated use of generative AI at large corporations has also accelerated customer data leakage and presents new challenges for companies looking to maintain security compliance. At AVM, we believe that the accelerated adoption of Generative AI needs the strict adoption of advanced security protocols.
Contact:Julie [email protected]
Logo – https://mma.prnewswire.com/media/2430009/AVM_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/add-value-machine-adcb-and-amazon-web-services-aws-successfully-conclude-uaes-first-ever-generative-ai-hackathon-in-the-banking-sector-302173328.html
Artificial Intelligence
Altair One® Cloud Innovation Gateway Now Available on Google Cloud Marketplace
Addition will expand access to Altair’s digital engineering experience
TROY, Mich., June 17, 2024 /PRNewswire/ — Altair (Nasdaq: ALTR), a global leader in computational intelligence, announced that Altair One®, Altair’s cloud innovation gateway, is now available on Google Cloud Marketplace, opening up a world of possibilities for users seeking seamless access to powerful simulation, data analytics, and high-performance computing (HPC) capabilities.
Altair One is designed for collaborative engineering, data engineering, and analytical application development. Built on a robust HPC backbone, Altair One provides seamless, unified access to tools, data, and computing resources while unleashing the power of artificial intelligence (AI) across every step of the product development life cycle.
Google Cloud Marketplace customers can now leverage Bring Your Own Cloud (BYOC) functionality to run Altair simulation, AI, and data analytics applications.
“The integration of Altair One with the Google Cloud Marketplace empowers Google Cloud users to effortlessly unlock a world of innovative solutions. This collaboration will fuel engineering breakthroughs with the power of Google Cloud’s adaptable, flexible, and scalable cloud infrastructure,” said Sam Mahalingam, chief technology officer, Altair. “This integration aligns perfectly with our core mission of equipping businesses for digital success and making powerful software solutions readily accessible to users.”
“Bringing Altair One to Google Cloud Marketplace will help customers quickly deploy, manage, and grow the platform on Google Cloud’s trusted, global infrastructure,” said Dai Vu, managing director, Marketplace and ISV GTM Programs, Google Cloud. “Altair can continue to securely scale and support customers on their digital transformation journeys.”
Altair One is the gateway that empowers organizations to mature into digital enterprises by breaking down data silos, connecting virtual models, optimizing their compute infrastructure, and digitizing key processes. It provides all the tools to create a “One Total Twin” of a product throughout its lifecycle, “One Traceable Thread” connecting all data stages, and a “Single Source of Truth” for all models and data. This all-in-one platform automates data capture, empowers better decision-making, enhances performance management, and ultimately accelerates engineering processes for a seamless digital experience.
To learn more, visit https://console.cloud.google.com/marketplace/product/altair/altair-one-private?hl=en&project=altair-public.
About Altair
Altair is a global leader in computational intelligence that provides software and cloud solutions in simulation, high-performance computing (HPC), data analytics, and AI. Altair enables organizations across all industries to compete more effectively and drive smarter decisions in an increasingly connected world – all while creating a greener, more sustainable future. To learn more, please visit www.altair.com.
Media contacts
Altair Corporate
Altair Investor Relations
Bridget Hagan
Stephen Palmtag
+1.216.769.2658
+1.669.328.9111
[email protected]
[email protected]
Altair Europe/The Middle East/Africa
Charlotte Hartmann
+49 7031 6208 0
[email protected]
Photo – https://mma.prnewswire.com/media/2438952/Altair_AltairOne_Google_Marketplace.jpgLogo – https://mma.prnewswire.com/media/1421069/Altair_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/altair-one-cloud-innovation-gateway-now-available-on-google-cloud-marketplace-302173139.html
Artificial Intelligence
IBS Software Announces Appointment of New Chief Executive Officer Somit Goyal
DUBAI, UAE, June 17, 2024 /PRNewswire/ — IBS Software, a leading SaaS solutions provider to the travel industry globally, has appointed Somit Goyal as its new Chief Executive Officer (CEO), effective immediately. Somit succeeds Anand Krishnan, who served as CEO of IBS Software since 2018.
Somit Goyal brings a wealth of experience in the enterprise software sector, having held leadership roles at globally renowned companies such as Microsoft, SAP, Oracle and AOL.
During his 11-year tenure at Microsoft, Somit held several leadership roles across strategy, operations, sales and customer success. In his last role, he managed the global sales of Microsoft’s Modern Work cloud business, and before that, Somit served as the Chief Operating Officer of Microsoft’s Public Sector business worldwide. Somit also conceived and established the Customer Success function at Microsoft, an area of growing importance for IBS Software as it continues to expand globally.
Most recently, Somit served as President and COO of Pluralsight, a SaaS company, where he oversaw product, engineering and GTM functions.
“Somit’s impressive experience in operating global SaaS businesses, leading diverse teams, and managing all facets of enterprise software make him exceptionally well-suited to lead IBS Software during this exciting phase of growth,” said V K Mathews, Executive Chairman of IBS Software. “IBS Software is at a pivotal point in its trajectory as we continue to innovate to better serve our customers. I am confident Somit will help unlock our full potential.”
With a comprehensive portfolio of modular, cloud-based solutions purpose-built for the travel industry, IBS Software helps travel companies accelerate innovation and drive efficiency across a broad set of core business processes, including passenger services, flight operations, cargo and logistics, loyalty management, cruise operations, energy & resource logistics and hospitality businesses.
“With a broad portfolio of industry leading products, marquee customers and a talented team, with deep domain expertise IBS Software stands at the forefront of travel industry innovation. I couldn’t be more excited to join IBS Software and help lead it through its next exciting chapter.” said Somit Goyal, who holds an electrical engineering degree from the Indian Institute of Technology (IIT) in New Delhi, India and an MBA from INSEAD, France.
Somit will report directly to IBS Software Executive Chairman V K Mathews.
ABOUT IBS SOFTWARE
IBS Software is a leading SaaS solutions provider to the travel industry globally, managing mission-critical operations for customers in the aviation, tour & cruise, hospitality, and energy resources industries. IBS Software’s solutions for the aviation industry cover fleet & crew operations, aircraft maintenance, passenger services, loyalty programs, staff travel and air cargo management. Across the hospitality sector, IBS Software offers a cloud-native, unified platform for hotels and travel sellers, including central reservation (CRS), property management (PMS), revenue management (RMS), call centre, booking engine, loyalty and distribution. For the tour & cruise industry, IBS provides a comprehensive, customer-centric, digital platform that covers onshore, online and on-board solutions. Across the energy & resources industry, we provide logistics management solutions that cover logistics planning, operations & accommodation management. The Consulting and Digital Transformation (CDx) business focuses on driving digital transformation initiatives of its customers, leveraging its domain knowledge, digital technologies and engineering excellence. IBS Software operates from 17 offices across the world.
Further information can be found at www.ibsplc.com Follow us: Blog | Twitter | LinkedIn | Facebook | Instagram
Photo – https://mma.prnewswire.com/media/2439582/IBS_Software.jpgLogo – https://mma.prnewswire.com/media/1169353/IBS_Software_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/ibs-software-announces-appointment-of-new-chief-executive-officer-somit-goyal-302173590.html
-
Artificial Intelligence7 days agoADP Rings NASDAQ Opening Bell Celebrates 75 Years at the Forefront of Payroll & HR Innovation
-
Artificial Intelligence7 days agoTraceLink Partners with Genpact to Expand Delivery of Digital Supply Chain Innovation for Healthcare and Life Sciences Sectors
-
Artificial Intelligence3 days agoBorderless AI & Cohere team up to build a custom-trained AI model for HR professionals, taking on Deel and Remote.com
-
Artificial Intelligence7 days agoEmpowering data practitioners will help shape generative AI deployment for enterprise, says new MIT Technology Review Insights research report
-
Uncategorized6 days agoHughes Europe Expands into Military, Defence & Government Sectors with Launch of Konnect VHTS Services in Collaboration with Telespazio
-
Uncategorized5 days ago
AI Could Transform UK’s Public Finances as Labour Touts Gains
-
Artificial Intelligence3 days agoLoRa and LoRaWAN IoT Market worth $32.7 billion by 2029- Exclusive Report by MarketsandMarkets™
-
Artificial Intelligence3 days ago
Complyport’s new AI tool – ViCA.Chat – set to revolutionise compliance support services
